PubMed Health⌕ Search

Biomedical subjects

A Klassen

Publications and source records attributed to A Klassen.

26 records · Page 2Linked to original sources
PubMed1996

Patients' health related quality of life before and after aesthetic surgery.

OBJECTIVES: To assess the health related quality of life of patients before and after aesthetic surgery. DESIGN: A survey by questionnaire of patients before receiving surgery and 6 months after surgery. SAMPLE: 656 patients anticipating surgery were sent a preoperative questionnaire, to which 443 replied. Subsequently 259 of these received a postoperative questionnaire, of which 198 were returned. OUTCOME MEASURES: Health status was assessed using three standardised health status instruments (The Short Form 36 Health Survey Questionnaire (SF-36), the General Health Questionnaire (GHQ-28) and the Rosenberg Self Esteem Scale. Comparisons were made between the health status of the plastic surgery patients and that of a random sample of the general population. RESULTS: Patients receiving breast reduction surgery experienced significant improvements on all three health status measures. Patients in all surgical groups experienced significant improvements in self-esteem. CONCLUSIONS: Patients receiving aesthetic surgery experience a wide range of physical, psychological and social problems. Surgery was shown be effective at addressing these problems. Health status assessment provides a valid and independent method for measuring the effects of such health care interventions.

Abdomen↗
PubMed1993

Diagnostic dilatation and curettage: is it used appropriately?

OBJECTIVE: To determine patterns of use of dilatation and curettage in Britain as compared with those in the United States; to examine variations in utilisation rates within one regional health authority. DESIGN: Analysis of routinely collected hospital inpatient statistics. SETTING: Statistics for England, Scotland, and the United States; local statistics for Oxford region. SUBJECTS: All inpatient episodes in which dilatation and curettage was performed but excluding those related to pregnancy. RESULTS: Dilatation and curettage rates remained stable in Britain between 1977 and 1990, whereas in the United States they declined dramatically. In 1989-90 the rate was 71.1 per 10,000 women in England as compared with only 10.8 per 10,000 in America. In 1989, 6936 women underwent diagnostic dilatation and curettage in the Oxford region, making it the most common elective operation. A total of 2726 (39%) of these women were under 40. There was a more than twofold variation in usage of the procedure among district health authorities within the region and even greater variation in rates in women under 40. The proportion of patients treated as day cases in the district general hospitals ranged from 22% to 82%. CONCLUSIONS: Dilatation and curettage may frequently be used inappropriately. The considerable variations in usage of dilatation and curettage internationally and nationally indicate differences in clinical perception of its appropriateness. This makes it suitable for audit. In developing guidelines it will be important to agree on the most appropriate patients and the relative merits of alternative methods of endometrial sampling. Probably this could result in considerable cost savings at no risk and possibly some benefit to patients.

Adolescent↗
PubMed1987

[The demonstration of proteolytic activity of bovine coronary arteries and the effect of drugs and other substances on it].

Intracellular neutral proteinases activity of bovine coronary arteries was demonstrated, isolated and partially characterized. The enriched crude enzyme preparation can be inhibited by diisopropylphosphofluoridate (DFP) and phenylmethylsulfonylfluoride (PMSF). The inhibitor concentration (pI50 values) by DFP and PMSF in the enzyme preparation and for trypsin are very similar. Several drugs (isoproterenol, propranolol, theophylline) tested on the enriched crude neutral proteinases preparation showed stimulatory or inhibitory activities. The results are discussed with regard to a possible action mechanism such proteinases on the cyclic AMP/cyclic GMP system.

Animals↗
PubMed1986

Choriocarcinoma with brain metastases. Successful management of increased intracranial pressure with barbiturates.

Choriocarcinoma is a potentially curable neoplasm. Although the presence of intracranial metastases worsens the ultimate prognosis, several reports have shown successful response to therapy. This clinical report outlines a method by which the appropriate therapy may be initiated in a patient with intracranial metastases, who otherwise may not have survived the interval necessary for the induction of successful therapy.

Adult↗
PubMed1970

Tumorigenesis in mouse skin: inhibition by synthetic inhibitors of proteases.

Three synthetic inhibitors of proteases (tosyl lysine chloromethyl ketone, tosyl phenylalanine chloromethyl ketone, and tosyl arginine methyl ester) inhibit the tumorigenesis initiated in mouse skin by 7,12-dimethylbenz(a)anthracene and promoted by croton oil or its active principle, phorbol ester. These protease inhibitors, when applied directly to mouse skin, inhibit some of the irritant effects of the tumor promoter and are not toxic.

Animals↗
PubMedDate not supplied

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.

OBJECTIVE: To evaluate the efficacy and tolerability of naratriptan, a novel 5-HT1 agonist, in the acute treatment of migraine. DESIGN/METHODS: Six hundred thirteen migraineurs, diagnosed according to International Headache Society criteria, treated a single migraine attack with naratriptan tablets (2.5 mg, 1 mg, 0.25 mg, or 0.1 mg) or placebo in a randomized, double-blind, placebo-controlled, parallel-group study conducted at 54 United States centers. At dosing and at predetermined intervals beginning 30 minutes postdose, patients recorded migraine pain severity, clinical disability, and presence of associated migraine symptoms. Safety measures included adverse events, physical examinations, vital signs, ECGs, and clinical laboratory tests. RESULTS: Headache relief (moderate or severe pain at dosing reduced to mild or no pain) 4 hours postdose was reported in 60% of patients receiving naratriptan 2.5 mg compared with 50%, 35%, 32%, and 34% of patients receiving naratriptan 1 mg, 0.25 mg, 0.1 mg, and placebo, respectively (P < 0.05 naratriptan 2.5 mg and 1 mg versus placebo, 1 mg versus 0.1 mg, and 2.5 mg versus 0.1 mg and 0.25 mg). Clinical disability 4 hours postdose was reported as mild or none for 70% of patients receiving naratriptan 2.5 mg compared with 63%, 47%, 48%, and 48% of patients receiving naratriptan 1 mg, 0.25 mg, 0.1 mg, or placebo, respectively (P < 0.05 naratriptan 2.5 mg and 1 mg versus placebo, 1 mg versus 0.1 mg, and 2.5 mg versus 0.1 mg and 0.25 mg). Four-hour efficacy for absence of nausea, photophobia, and phonophobia was similar to efficacy for headache relief at each dose. The adverse event profile of each dose of naratriptan was similar to that of placebo. No clinically relevant change in any safety measure was reported. CONCLUSIONS: Naratriptan is effective and well tolerated for the acute treatment of migraine. The 2.5-mg dose appears to offer the optimum ratio of efficacy to tolerability.

Acute Disease↗